StonvexLoading…
StonvexStonvexStonvexCore line items from DOCN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $257.90M | $901.43M | $659.04M | $429.40M |
Operating Income | $36.57M | $156.99M | $118.19M | $73.26M |
Net Income | $15.77M | $259.26M | $233.60M | $75.23M |
EPS (Diluted) | $0.15 | $2.52 | $2.31 | $0.77 |
Total Assets | $2.57B | $1.84B | $1.73B | $1.72B |
Total Liabilities | $1.68B | $1.87B | $1.80B | $1.90B |
Cash & Equivalents | $741.36M | $254.47M | $236.56M | $387.75M |
Free Cash Flow OCF − CapEx | $6.93M | $180.52M | $149.39M | $61.38M |
Shares Outstanding | 104.32M | 91.95M | 91.47M | 91.11M |